Fisher & Paykel Healthcare Corporation Limited (FSPKF)
USD 18.36
(-16.55%)
USD 18.36
(-16.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 444.8 Million NZD | -15.1% |
| 2023 | 433.7 Million NZD | -28.33% |
| 2022 | 605.1 Million NZD | -25.13% |
| 2021 | 808.2 Million NZD | 85.62% |
| 2020 | 435.4 Million NZD | 28.97% |
| 2019 | 337.6 Million AUD | 6.8% |
| 2018 | 316.1 Million AUD | 12.48% |
| 2017 | 281.02 Million AUD | 14.06% |
| 2016 | 246.38 Million AUD | 22.05% |
| 2015 | 201.87 Million AUD | 15.8% |
| 2014 | 174.33 Million AUD | 23.91% |
| 2013 | 140.69 Million AUD | 21.67% |
| 2012 | 115.63 Million AUD | -3.95% |
| 2011 | 120.39 Million AUD | -0.46% |
| 2010 | 120.94 Million AUD | -0.01% |
| 2009 | 120.95 Million AUD | 61.07% |
| 2008 | 74.34 Million AUD | -27.57% |
| 2007 | 103.68 Million AUD | -9.65% |
| 2006 | 114.76 Million AUD | 13.91% |
| 2005 | 100.74 Million AUD | 12.24% |
| 2004 | 89.76 Million AUD | -25.27% |
| 2003 | 120.11 Million AUD | 17.87% |
| 2002 | 101.9 Million AUD | 310.39% |
| 2001 | 24.83 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | 123.2 Million NZD | 0.0% |
| 2024 Q2 | 219.1 Million NZD | 105.34% |
| 2024 Q3 | 123.2 Million NZD | -39.52% |
| 2024 FY | - NZD | 11.37% |
| 2024 Q1 | 99.2 Million NZD | -62.94% |
| 2023 Q1 | 84.75 Million NZD | -63.83% |
| 2023 Q2 | 181.1 Million NZD | 113.69% |
| 2023 Q4 | 257.6 Million NZD | 114.67% |
| 2023 FY | - NZD | -28.33% |
| 2023 Q3 | 120 Million NZD | -33.74% |
| 2022 Q4 | 234.3 Million NZD | 97.89% |
| 2022 Q1 | 170.85 Million NZD | -60.05% |
| 2022 FY | - NZD | -25.13% |
| 2022 Q2 | 328 Million NZD | 91.98% |
| 2022 Q3 | 118.4 Million NZD | -63.9% |
| 2021 Q1 | 170.6 Million NZD | -32.33% |
| 2021 Q3 | 220.05 Million NZD | -36.51% |
| 2021 Q4 | 427.7 Million NZD | 94.36% |
| 2021 FY | - NZD | 85.62% |
| 2021 Q2 | 346.6 Million NZD | 103.17% |
| 2020 Q1 | 94.9 Million NZD | 1.93% |
| 2020 Q4 | 252.1 Million NZD | 113.83% |
| 2020 Q3 | 117.9 Million NZD | -40.42% |
| 2020 FY | - NZD | 28.97% |
| 2020 Q2 | 197.9 Million NZD | 108.54% |
| 2019 FY | - AUD | 6.8% |
| 2019 Q4 | 93.1 Million NZD | 0.0% |
| 2019 Q3 | 93.1 Million NZD | 11.1% |
| 2019 Q2 | 83.8 Million NZD | 0.0% |
| 2019 Q1 | 83.8 Million NZD | -2.73% |
| 2018 Q3 | 86.15 Million NZD | 24.4% |
| 2018 FY | - AUD | 12.48% |
| 2018 Q1 | 69.25 Million NZD | -4.68% |
| 2018 Q2 | 69.25 Million NZD | 0.0% |
| 2018 Q4 | 86.15 Million NZD | 0.0% |
| 2017 Q1 | 65.3 Million NZD | -1.16% |
| 2017 FY | - AUD | 14.06% |
| 2017 Q4 | 72.65 Million NZD | 0.0% |
| 2017 Q3 | 72.65 Million NZD | 11.26% |
| 2017 Q2 | 65.3 Million NZD | 0.0% |
| 2016 Q4 | 66.06 Million NZD | 0.0% |
| 2016 Q3 | 66.06 Million NZD | 18.45% |
| 2016 Q2 | 55.77 Million NZD | 0.0% |
| 2016 Q1 | 55.77 Million NZD | -0.06% |
| 2016 FY | - AUD | 22.05% |
| 2015 Q1 | 44.14 Million NZD | -2.41% |
| 2015 Q3 | 55.8 Million NZD | 26.42% |
| 2015 Q4 | 55.8 Million NZD | 0.0% |
| 2015 FY | - AUD | 15.8% |
| 2015 Q2 | 44.14 Million NZD | 0.0% |
| 2014 Q1 | 40.7 Million NZD | 5.37% |
| 2014 FY | - AUD | 23.91% |
| 2014 Q3 | 45.23 Million NZD | 11.14% |
| 2014 Q2 | 40.7 Million NZD | 0.0% |
| 2014 Q4 | 45.23 Million NZD | 0.0% |
| 2013 Q4 | 38.62 Million NZD | 0.0% |
| 2013 Q3 | 38.62 Million NZD | 0.0% |
| 2013 FY | - AUD | 21.67% |
| 2012 FY | - AUD | -3.95% |
| 2011 FY | - AUD | -0.46% |
| 2010 FY | - AUD | -0.01% |
| 2009 FY | - AUD | 61.07% |
| 2008 FY | - AUD | -27.57% |
| 2007 FY | - AUD | -9.65% |
| 2006 FY | - AUD | 13.91% |
| 2005 FY | - AUD | 12.24% |
| 2004 FY | - AUD | -25.27% |
| 2003 FY | - AUD | 17.87% |
| 2002 FY | - AUD | 310.39% |
| 2001 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 46243.281% |
| Ansell Limited | 209.86 Million USD | -111.95% |
| Ansell Limited | 206.3 Million USD | -115.608% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 42.83 Million USD | -938.287% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 27473.133% |
| Psykey, Inc. | -1.29 Million USD | 34439.429% |
| ConvaTec Group Plc | 455.5 Million USD | 2.349% |
| ConvaTec Group Plc | 455.5 Million USD | 2.349% |
| Encision Inc. | -544.19 Thousand USD | 81835.407% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 313759.121% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 404721.123% |
| Innovative MedTech Inc. | -7.67 Million USD | 5896.333% |
| LifePoint, Inc. | -14.2 Million USD | 3231.923% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 7289.268% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 136961.538% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -215.23 Thousand USD | 206758.799% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 109714.968% |
| SmileDirectClub, Inc. | -186.13 Million USD | 338.961% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | 0.675% |
| SheerVision, Inc. | -110.53 Thousand USD | 402521.04% |
| United Health Products, Inc. | -2.5 Million USD | 17876.257% |
| Vasamed, Inc. | -4.57 Million USD | 9823.59% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 19775.008% |
| Yubo International Biotech Limited | -1.17 Million USD | 37868.981% |